The National Advertising Review Board determined that certain claims made by Matrixx Initiatives for its Zicam Cold Remedy products would not reasonably be understood to mean that use of the products prevents colds.
The National Advertising Division on Friday recommended that Matrixx Initiatives discontinue advertising claims that suggest its homeopathic Zicam Cold Remedy products prevent users from catching a cold.
ProPhase Labs on Monday again rejected an acquisition proposal from Matrixx Initiatives. Matrixx's latest offer was to acquire ProPhase for $1.60 per share in cash, up from a prior $1.40 per share proposal.
ProPhase Labs on Monday announced that it rejected an unsolicited, nonbinding proposal from Matrixx Initiatives to acquire the company for $1.40 per share in cash, subject to further due diligence by Matrixx.
With former Wyeth executive Dennis O’Donnell at the helm, Matrixx Initiatives is making a headquarter transition from Phoenix to here in New Jersey, according to a story published in the Arizona Republic earlier this week.
NEW YORK — The second half of the 2010-2011 cough-cold-flu season actually may realize greater sales of symptom relievers than last year, judging from the four weeks ended Dec. 26. According to Matrixx president and CEO Bill Hemelt, sales of remedies were on the rise in those four weeks. Hemelt noted that the total cough-cold category was 5% higher than the same period last year and growing.
Matrixx Initiatives on Friday provided a summary of the ongoing "go-shop" process initiated by the company after Wonder Holdings proposed a merger agreement. The “go-shop” process is scheduled to run through Jan. 22.
Cough-cold supplier Matrixx on Thursday credited tough comparisons against the prior season’s high pre-season inventory purchases by retailers due to the publicity of the H1N1 flu outbreak for the lower level of sales for the quarter ended Dec. 31, 2010.